Trial Profile
Safety and eficity of 2.5mg prasugrel therapy in the eldely or low body weight Japanese patients undergoing percutaneous coronary intervention
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 23 Jul 2018
Price :
$35
*
At a glance
- Drugs Prasugrel (Primary)
- Indications Ischaemic heart disorders
- Focus Therapeutic Use
- 29 Jun 2018 Primary endpoint (comparison of the prevalence of LPR between the 2.5-mg and 3.75-mg maintenance doses of prasugrel) has been met.
- 29 Jun 2018 Status changed from recruiting to discontinued.
- 29 Jun 2018 Results published in the Circulation Journal.